Mucosa-associated Lymphoid Tissue (MALT) Lymphoma - Pipeline Insight, 2021
This report can be delivered to the clients within 48 hours
DelveInsight’s, “Mucosa-associated Lymphoid Tissue (MALT) Lymphoma – Pipeline Insight, 2021,” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Mucosa-associated Lymphoid Tissue (MALT) Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Mucosa-associated Lymphoid Tissue (MALT) Lymphoma: Overview
MALT lymphoma belongs to a group of non-Hodgkin lymphomas called marginal zone lymphomas. It is a low grade (slow growing) non-Hodgkin lymphoma (NHL) that starts in the mucosa which lines some body organs and cavities. MALT lymphoma can affect people of any age but it typically develops in people in their mid-60s. MALT lymphoma is more common in people who have been infected with certain viruses or who have particular autoimmune conditions. The symptoms of MALT lymphoma depend on where the lymphoma develops. Unlike many other types of lymphoma, MALT lymphoma develops outside the lymph nodes. It does not usually cause swollen lymph nodes. People with MALT lymphoma very rarely experience ‘B symptoms. MALT lymphoma is usually diagnosed by removing a sample of tissue and looking at it under a microscope. This involves a small operation called a biopsy, which is usually done under a local anaesthetic. Surgery is used very occasionally if the lymphoma is only affecting one part of body and is in an area where it can be safely removed.
'Mucosa-associated Lymphoid Tissue (MALT) Lymphoma - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Mucosa-associated Lymphoid Tissue (MALT) Lymphoma pipeline landscape is provided which includes the disease overview and Mucosa-associated Lymphoid Tissue (MALT) Lymphoma treatment guidelines. The assessment part of the report embraces, in depth Mucosa-associated Lymphoid Tissue (MALT) Lymphoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Mucosa-associated Lymphoid Tissue (MALT) Lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Mucosa-associated Lymphoid Tissue (MALT) Lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Emerging Drugs
Further product details are provided in the report……..
Mucosa-associated Lymphoid Tissue (MALT) Lymphoma: Therapeutic Assessment
This segment of the report provides insights about the different Mucosa-associated Lymphoid Tissue (MALT) Lymphoma drugs segregated based on following parameters that define the scope of the report, such as:
Mucosa-associated Lymphoid Tissue (MALT) Lymphoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Mucosa-associated Lymphoid Tissue (MALT) Lymphoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Mucosa-associated Lymphoid Tissue (MALT) Lymphoma drugs.
Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Mucosa-associated Lymphoid Tissue (MALT) Lymphoma – Pipeline Insight, 2021,” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Mucosa-associated Lymphoid Tissue (MALT) Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Mucosa-associated Lymphoid Tissue (MALT) Lymphoma: Overview
MALT lymphoma belongs to a group of non-Hodgkin lymphomas called marginal zone lymphomas. It is a low grade (slow growing) non-Hodgkin lymphoma (NHL) that starts in the mucosa which lines some body organs and cavities. MALT lymphoma can affect people of any age but it typically develops in people in their mid-60s. MALT lymphoma is more common in people who have been infected with certain viruses or who have particular autoimmune conditions. The symptoms of MALT lymphoma depend on where the lymphoma develops. Unlike many other types of lymphoma, MALT lymphoma develops outside the lymph nodes. It does not usually cause swollen lymph nodes. People with MALT lymphoma very rarely experience ‘B symptoms. MALT lymphoma is usually diagnosed by removing a sample of tissue and looking at it under a microscope. This involves a small operation called a biopsy, which is usually done under a local anaesthetic. Surgery is used very occasionally if the lymphoma is only affecting one part of body and is in an area where it can be safely removed.
'Mucosa-associated Lymphoid Tissue (MALT) Lymphoma - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Mucosa-associated Lymphoid Tissue (MALT) Lymphoma pipeline landscape is provided which includes the disease overview and Mucosa-associated Lymphoid Tissue (MALT) Lymphoma treatment guidelines. The assessment part of the report embraces, in depth Mucosa-associated Lymphoid Tissue (MALT) Lymphoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Mucosa-associated Lymphoid Tissue (MALT) Lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Mucosa-associated Lymphoid Tissue (MALT) Lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve Mucosa-associated Lymphoid Tissue (MALT) Lymphoma.
This segment of the Mucosa-associated Lymphoid Tissue (MALT) Lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Emerging Drugs
- Tafasitamab: Morphosys
- Zandelisib/ MEI Pharma
Further product details are provided in the report……..
Mucosa-associated Lymphoid Tissue (MALT) Lymphoma: Therapeutic Assessment
This segment of the report provides insights about the different Mucosa-associated Lymphoid Tissue (MALT) Lymphoma drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Mucosa-associated Lymphoid Tissue (MALT) Lymphoma
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Mucosa-associated Lymphoid Tissue (MALT) Lymphoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Mucosa-associated Lymphoid Tissue (MALT) Lymphoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Mucosa-associated Lymphoid Tissue (MALT) Lymphoma drugs.
Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Report Insights
- Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Mucosa-associated Lymphoid Tissue (MALT) Lymphoma drugs?
- How many Mucosa-associated Lymphoid Tissue (MALT) Lymphoma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Mucosa-associated Lymphoid Tissue (MALT) Lymphoma?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Mucosa-associated Lymphoid Tissue (MALT) Lymphoma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Mucosa-associated Lymphoid Tissue (MALT) Lymphoma and their status?
- What are the key designations that have been granted to the emerging drugs?
Introduction
Executive Summary
Mucosa-associated Lymphoid Tissue (MALT) Lymphoma: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Tafasitamab: Morphosys
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early stage products (Phase I/II)
Comparative Analysis
LOXO-305: Loxo Oncology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Key Companies
Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Key Products
Mucosa-associated Lymphoid Tissue (MALT) Lymphoma- Unmet Needs
Mucosa-associated Lymphoid Tissue (MALT) Lymphoma- Market Drivers and Barriers
Mucosa-associated Lymphoid Tissue (MALT) Lymphoma- Future Perspectives and Conclusion
Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Analyst Views
Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Key Companies
Appendix
Executive Summary
Mucosa-associated Lymphoid Tissue (MALT) Lymphoma: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Tafasitamab: Morphosys
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early stage products (Phase I/II)
Comparative Analysis
LOXO-305: Loxo Oncology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Key Companies
Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Key Products
Mucosa-associated Lymphoid Tissue (MALT) Lymphoma- Unmet Needs
Mucosa-associated Lymphoid Tissue (MALT) Lymphoma- Market Drivers and Barriers
Mucosa-associated Lymphoid Tissue (MALT) Lymphoma- Future Perspectives and Conclusion
Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Analyst Views
Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Mucosa-associated Lymphoid Tissue (MALT) Lymphoma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Mucosa-associated Lymphoid Tissue (MALT) Lymphoma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Mucosa-associated Lymphoid Tissue (MALT) Lymphoma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Mucosa-associated Lymphoid Tissue (MALT) Lymphoma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products